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NeurosyphilisNew-onset refractory status epilepticus (NORSE) is a syndrome of new-onset drug resistant status epilepticus
that often has a catastrophic outcome. A 30-year-old man of Somali origin presented with refractory status to
a district general hospital. A clinical diagnosis of NORSE syndrome was made, and he was transferred to the re-
gional epilepsy center for immunomodulatory treatment and consideration for cyclophosphamide treatment.
After transfer to the regional epilepsy center, his repeat cerebrospinal ﬂuid tested strongly positive for syphilis,
indicating a diagnosis of neurosyphilis, and the patient was treated with high-dose intravenous (IV)
benzylpenicillin. His status epilepticus abated 24 h later.
New-onset refractory status epilepticus syndrome is a diagnosis of exclusion. Before instigation of potentially
harmful neuromodulatory therapies, treatable causes such as neurosyphilis should be considered. We advocate
the early transfer of refractory status patients to a specialist epilepsy center for both seizure management and
cause determination.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
New-onset refractory status epilepticus (NORSE) is a syndromic
diagnosis recognized by de novo status, without a history of epilepsy,
in which no underlying structural, metabolic, or infective cause is
identiﬁed. The syndrome can have very prolonged status epilepticus;
it affects the young and healthy and frequently has a catastrophic
outcome. Increasingly early aggressive intervention with immunomod-
ulatory treatment such as steroids, including cyclophosphamide is
advocated [1–4].2. Case presentation
A 31-year-old Somali gentleman, with no prior history of epilepsy,
presented with status epilepticus to his local district general hospital
following a nonspeciﬁc prodrome of feeling generally unwell and
weight loss for a few weeks. He was transferred to critical care, and ini-
tial treatment included phenytoin, ceftriaxone, and aciclovir. Over the
course of 5 days, his condition did not respond to treatment with four
antiepileptic drugs (AEDs). Additionally, the patient was sedated with
midazolam, alfentanil, and propofol. Despite these measures, daily
EEGs showed suboptimal control of seizure activity.. This is an open access article underThe patient's blood tests revealed a raised CRP, negative viral PCR
(including hepatitis and HIV), negative blood cultures, and negative
urine cultures. Initial lumbar puncture revealed a raised protein of
1.36 g/L, 0 polymorphs × 106/L, 20 mononuclear cells × 106/L, and a
CSF glucose level less than half the serum glucose level (4.2/10.2), but
no organisms were seen on the Gram stain. (See Table 1 in the
Supplementary evidence for full tests.)
Head MRI showed a slightly increased signal in the anterior left
temporal lobe on axial ﬂair sequence. The patient was given empirical
treatment for suspected new-onset refractory status epilepticus
syndrome (NORSE) with 3 days of high-dose methylprednisolone and
subsequently maintained on 60-mg prednisolone. The treating
neurological team made a clinical diagnosis of new-onset refractory
status epilepticus (NORSE) syndrome. On day 9 of his admission, he
was transferred to the ITU department of the tertiary epilepsy center
with the intention of giving plasma exchange and for consideration of
cyclophosphamide treatment.
A further review at the specialist center revealed a previous diagno-
sis of treated genital syphilis 3 years ago. A repeat CSF examination was
sent for treponemal serology; this came back as strongly positive in
serum and CSF strongly indicating a diagnosis of neurosyphilis.
❖ Initial treponemal serology screen:
○ CSF RPR (rapid plasma reagin test) 1:4, TPPA (Treponema pallidum
particle agglutination) 1:10,240,
○ serum VDRL (venereal disease reference laboratory) 1:4, serum
TPPA 1:20,480.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 2. Repeat axial brain MRI scan at 1 month.
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2.4 g QDS for neurosyphilis in line with national guidelines. The
patient's EEG demonstrated dramatic improvement in the next 24 h
with no further electrographic or clinical seizures.
❖ Repeat syphilis screen 6 days later (posttreatment):
○ CSF RPR negative, TPPA negative,
○ serum RPR 1:2, TPPA 1:10, 240.
The repeat axial head MRI at 1 month demonstrated ‘marked inter-
val reduction in cerebral volume showing a central pattern of atrophy
with enlargement of the lateral and third ventricles.’
Figs. 1 and 2 show the initial and repeat axial brain MRI scans at
1 month, respectively.
3. Outcome and follow-up
At 12-month follow-up, the patient remains with gross functional
deﬁcits and marked cognitive impairment and requires full nursing
care including percutaneous endoscopic gastrostomy tube for feeding.
4. Discussion
New-onset refractory status epilepticus syndrome affects the young
and is often associated with a poor neurological outcome [1]. Increas-
ingly, it is considered to have an immune basis, and therefore aggressive
immunomodulatory therapy is advocated at an early stage [2,3]. How-
ever, clinicians must remember that NORSE syndrome is a diagnosis
made by excluding other causes, some of which such as neurosyphilis
are readily treatable (see Table 2 in the Supplementary evidence for a
list of known causes).
The incidence of seizures in neurosyphilis from studies is reported to
range from 14 to 60%, but status epilepticus (SE) as the presenting
symptom is very rare [5–7]. Furthermore, there are only a handful of
cases of patients presentingwith refractory status epilepticus secondary
to neurosyphilis [6,7]. Neurosyphilis presents diversely and is known toFig. 1. Initial axial brain MRI scan at 1 month.have the ability to infect the nervous system at any stage of infection.
The standard dose given for the treatment of syphilis is insufﬁcient in
treating neurosyphilis, and treatment iswith high-dose benzylpenicillin
[4,6–8].
While this case had the clinical characteristics of other cases of
NORSE syndrome seen at our center, the history of ‘treated’ syphilis
was a clue to the underlying cause. Wewould advocate that all patients
with refractory status are tested for syphilis, allowing for early instiga-
tion of directed antibiotic therapy and avoidance of cytotoxic therapy.
An etiological factor needs to be identiﬁed and be treated; this case em-
phasizes the need to perform an extensive workup as early as possible,
and given the complexities of managing and determining the cause of
status epilepticus, we suggest such patients should be transferred to a
regional neuroscience center early in their illness.
5. Conclusion
New-onset refractory status epilepticus syndrome is a diagnosis of
exclusion. Before instigation of potentially harmful neuromodulatory
therapies, treatable causes such as neurosyphilis should be considered.
We advocate early transfer of refractory status patients to a specialist
epilepsy center experienced in rapidly managing refractory epilepsy
for both seizure management and cause determination.
6. Learning points/conclusion
Any patient that is admitted with refractory epilepsy should have a
full extensive search done to ﬁnd a causative agent.
New-onset refractory status epilepticus syndrome is a diagnosis of
exclusion and is increasingly treated with immunomodulatory thera-
pies such as cyclophosphamide — always consider treatable causes
such as neurosyphilis.
Neurosyphilis can present with status epilepticus.
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